Skip to content
Menu

Quantum BioPharma Ltd. QNTM

Full chart Compare
Set alert

Price alert · QNTM

All alert types
1.44 USD -0.17 (-10.56%)

Regular-session close

1.45 +0.01 +0.69%

After hours · Nov 16, 6:13 PM ET

1.33 Day range 1.59
1.33 52-week range 12.42
YTD
-80.27%
1 year
-80.43%
Market cap
9.26M
EPS (ttm)
-4.48
Shares out
1.92M
Forward P/E
-0.41
YTD return
-80.27%
1-year return
-80.43%
Volume
122.85K
Avg volume
171.36K
Open
1.59
Previous close
1.61
Day's range
1.33 – 1.59
52-week range
1.33 – 12.42

5D -0.73 (-33.33%)

1.502TueWedThuFriMon1.46

Key statistics

50-day average
4.92
200-day average
14.62
Enterprise value
-4.42M
Price / book
0.18
Free cash flow
-9.24M
Total cash
6.61M
Total debt
373.02K
Return on equity
-73.84%
Short % of float
0.33%

Fundamental scorecard

5 of 25 checks passed on QNTM’s reported financials

ValueGrowthProfitabilityHealthDividend

5of 25 checks passed

  • Value 1 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend No data

Statements to Sep 30, 2026.

Financials — quick view

All financials
QNTM Revenue — quarterly 0
QNTM Net income — quarterly -297.09K
QNTM EPS — quarterly -0.06

Earnings

QNTM recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 11, 2024Sep 1, 2024-2.78-4.37-1.59-57.19%

About Quantum BioPharma Ltd.

Quantum BioPharma Ltd., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd., is headquartered in Toronto, Canada.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
Canada

News

Your note

Sign in to keep a note on QNTM — it syncs with the Stock Master app.

Institution ownership

QNTM institution ownership
Holder% heldSharesValueReported
AdvisorShares Investments, LLC1.37%26,23384.21KSep 29, 2024
Virtu Financial LLC0.60%11,42836.68KSep 29, 2024
HRT Financial LP0.52%10,04132.23KSep 29, 2024
Royal Bank of Canada0.01%107343Sep 29, 2024
Group One Trading, L.P.0.01%172552Sep 29, 2024
National Bank of Canada/FI0.00%48154Sep 29, 2024

Fund ownership

QNTM fund ownership
Holder% heldSharesValueReported
AdvisorShares Trust-AdvisorShares Psychedelics ETF3.69%70,898227.58KOct 30, 2024